Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

BACKGROUND: ALK gene rearrangement defines a new molecular subtype of non-small-cell lung cancer (NSCLC). In a recent phase 1 clinical trial, the ALK tyrosine-kinase inhibitor (TKI) crizotinib showed marked antitumour activity in patients with advanced, ALK-positive NSCLC. To assess whether crizotin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Shaw, Alice T, Yeap, Beow Y, Solomon, Benjamin J, Riely, Gregory J, Gainor, Justin, Engelman, Jeffrey A, Shapiro, Geoffrey I, Costa, Daniel B, Ou, Sai-Hong I, Butaney, Mohit, Salgia, Ravi, Maki, Robert G, Varella-Garcia, Marileila, Doebele, Robert C, Bang, Yung-Jue, Kulig, Kimary, Selaru, Paulina, Tang, Yiyun, Wilner, Keith D, Kwak, Eunice L, Clark, Jeffrey W, Iafrate, A John, Camidge, D Ross
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2011
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3328296/
https://ncbi.nlm.nih.gov/pubmed/21933749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(11)70232-7
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge